Publication Date:
2017-04-20
Description:
Chronic graft-versus-host disease (cGVHD) is frequent and severe after allogeneic hematopoietic stem cell transplantation (AHSCT), with unmet therapeutic needs. 1 A recent retrospective study has shown the potential efficacy of ruxolitinib, a selective Janus Kinase (JAK) 1/2 inhibitor, for the treatment of acute (n=54) and chronic GVHD (n=41) with a 81.5% and 85.4% overall response rate for acute and chronic GVHD respectively. 3 There are no specific studies evaluating the efficacy of ruxolitinib in sclerodermatous skin cGVHD, a rare and difficult-to-treat form of cGVHD. This article is protected by copyright. All rights reserved.
Print ISSN:
0007-0963
Electronic ISSN:
1365-2133
Topics:
Medicine
Permalink